Citi raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $575 from $550 and keeps a Buy rating on the shares. The firm upped the price target after adding povetacicept to the company’s model.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals Hold Rating: Key Factors and Challenges in the IgA Nephropathy Market
- Vertex Pharmaceuticals’ Strategic Acquisition and FDA Breakthrough Designation Boosts Buy Rating
- Morning Movers: CarMax slips following second quarter results
- Vertex Pharmaceuticals granted breakthrough therapy designation for povetacicept
- Vertex Pharmaceuticals completes enrollment in IA cohort of AMPLITUDE trial